Klotho

Klotho is a 1,012-amino-acid, roughlyundefinedkDa transmembrane protein—not an injectable peptide. Human studies only show that circulating alpha-klotho tracks with healthier aging; they do not show that taking it extends life. No legitimate consumer klotho vial or klotho supplement contains this protein, and current interventions use experimental plasmid or mRNA delivery.

Key facts

• What it is: a large protein made mainly in the kidneys, with a soluble form found in blood
• Evidence tier: human observational for aging associations; no completed human efficacy trial
• U.S. status (July 2026): investigational, with no FDA-approved product or indication
• How researchers deliver it: plasmid DNA or mRNA, not a reconstituted peptide vial
• Known risks: human frequencies are unknown because the intervention trials have not reported results
• Sport: klotho is not named on the 2026 WADA list, but performance-enhancing gene or cell doping is prohibited

What is klotho?

Klotho is the protein encoded by the human KL gene. The reviewed UniProt record lists 1,012 amino acids and a calculated mass of 116,181 daltons. That makes the klotho protein roughly 80 times heavier than BPC-157. Calling it a “peptide” may fit a store menu, but not the molecule.

Alpha-klotho begins anchored through a cell membrane. Enzymes can cut off its large outside portion, creating soluble alpha-klotho that circulates in blood. This profile is about alpha-klotho, not the related beta-klotho protein. The distinction matters because “klotho longevity” claims often blur the gene, membrane protein, soluble protein, and an experimental therapy into one convenient word.

How does alpha-klotho work?

Alpha-klotho helps fibroblast growth factor 23 (FGF23) send its signal through an FGF receptor, especially in the kidney. Picture a two-part lock: the receptor is present, but FGF23 needs klotho beside it to fit properly. That system controls phosphate handling and active vitamin D, while soluble klotho has additional proposed effects that remain less settled in humans.

The longevity label began with a 1997 mouse study. Mice with disrupted klotho expression developed short lifespan, infertility, artery disease, skin atrophy, osteoporosis, and emphysema. That discovery made klotho biology worth chasing. It did not show that giving klotho to people slows aging.

What does the human evidence show?

Human evidence is observational: healthier people often have higher circulating alpha-klotho, but association cannot tell whether klotho causes healthy aging or simply reflects kidney function, activity, disease burden, or other differences. The clean evidence grade is human observational, with an unknown intervention verdict. A biomarker is a dashboard light, not proof that replacing the light fixes the engine.

In 10,069 U.S. adults aged 40 to 79, lower serum klotho was associated with higher all-cause mortality during follow-up. The authors described klotho as a possible mortality-risk marker; they did not test a treatment. A 2026 systematic review and meta-analysis found links with frailty, physical function, and bone health, while cognitive findings were limited and inconsistent. Observational signals are useful for choosing what to test next, not permission to promise longer life.

Are klotho gene therapies real in 2026?

Two registered human studies are real, early, and easy to misdescribe. Neither injects ordinary klotho protein. Both give cells genetic instructions for making alpha-klotho, and neither has posted results. The delivery technology—not a peptide vial—is the intervention.

NCT07216781 is a 24-person, open-label Phase 1 pilot sponsored by Minicircle. The plasmid is injected under abdominal skin; the registry says administration occurs at GARM Clinic in Roatán, Honduras, outside U.S. FDA jurisdiction, while the Austin site performs assessments. Open-label and no placebo means any claimed health or cognitive change will be hard to separate from expectation and time.

NCT07544420 is Klothea Bio’s AKL003 Phase 1b study: 21 adults, randomized, double-blind, and placebo-controlled, with intravenous alpha-klotho mRNA. The registry listed it as not yet recruiting on July 16, 2026, despite a February company announcement saying recruitment had begun. That announcement places GARM in Próspera, Roatán, Honduras. The offshore location is not a footnote readers should have to excavate.

Is klotho safe?

Klotho intervention safety is unknown in healthy humans. The two registered trials are designed to measure safety, tolerability, laboratory changes, and protein expression; neither has supplied adverse-event rates. Plasmid and mRNA delivery also carry platform questions that cannot be answered by pointing to naturally occurring klotho in blood. “Your body makes it” is not a safety study.

The mineral-regulation mechanism is another reason to measure rather than guess: alpha-klotho participates in phosphate and vitamin D control. No long-term human trial has mapped what sustained artificial elevation does across organs. The honest risk list is therefore short but serious: procedure and delivery-system risks, unintended biological effects, and large unknowns about duration and reversibility.

Is there a real klotho supplement or injectable vial?

No legitimate consumer klotho vial exists, and a product sold as a “klotho supplement” is not the intact 116 kDa human klotho protein. At most, a supplement can claim that another ingredient supports the body’s own expression. That is a different claim requiring its own human evidence; the words on the bottle do not shrink a 1,012-amino-acid glycoprotein into a capsule.

Klotho also has no FDA-approved drug product or indication in the July 2026 Drugs@FDA reference. There is no established dose to report, nothing legitimate to reconstitute, and no evidence-based klotho stack. Retail vials should not be confused with the registered genetic interventions.

For context, the longevity peptide hub separates biomarkers, large proteins, true peptides, and experimental gene delivery. Follistatin creates a similar category problem: another large human protein whose gene-therapy research gets repackaged as a simple vial. The evidence-grading guide explains why both stay below an intervention-backed human tier, while the dated regulatory reference tracks what “investigational” means in practice.

Is klotho banned in sport?

Klotho is not named as a standalone substance on the 2026 WADA Prohibited List. The proposed klotho gene therapy is a separate question: WADA’s M3 section prohibits gene and cell doping with potential to enhance sport performance. Athletes should treat a performance-directed KL plasmid or mRNA intervention as a prohibited-method risk, not as an unlisted supplement loophole.

Klotho research has moved from mouse biology and human correlations into first-in-human genetic delivery. That is real progress. The proof that matters next is not a higher blood level or a glossy longevity claim; it is controlled human safety data followed by meaningful health outcomes. Until those arrive, klotho remains a compelling target, not an injectable longevity peptide.